Despite recent advances in current chemotherapy, the prognosis for locally advanced and
metastatic nonsmall‐cell cancer remains poor, and new approaches are required. An …

Molecularly targeted therapies have recently expanded the options available for patients
with advanced non-small-cell lung cancer (NSCLC). Two cancer cell pathways in particular …

Lung cancer is one of the most frequent causes of cancer-related death in the United States.
For patients with advanced non-small cell lung cancer (NSCLC), chemotherapy, alone or in …

Targeting cell-signalling pathways that confer survival advantage to cancer cells has
become a major focus of investigation for the treatment of various malignancies. Non-small …

Non-small-cell lung cancer (NSCLC) is characterized by wide molecular heterogeneity. In
recent years, novel agents that target specific, aberrant molecular pathways in NSCLC have …

Fifteen% or fewer of patients with non-small cell lung cancer (NSCLC) survive 5 years. The
current standard of care for patients with locally advanced or metastatic NSCLC is systemic …

Lung cancer is the most common cause of cancer death. The vast majority of patients
present with non-small cell lung cancer (NSCLC) in advanced inoperable stages. The …

Chemotherapy is the standard of care for patients with advanced non‐small cell lung cancer
(NSCLC). Over the past 20 years, advances in chemotherapy have shown minimal …

Systemic chemotherapy is the standard treatment for patients with advanced stage non-
small cell lung cancer (NSCLC) and improves both their survival and quality of life. Despite …

Targeted therapies have been largely employed in patients with advanced Non-Small Cell
Lung Cancer (NSCLC), and some of them have demonstrated consistent activity. Epidermal …